{"body": "The company announced its last quarter financial performance results on 12/15/2016. Oracle Corporation (NYSE:ORCL) belongs to Computer and Technology sector that declined -0.05% in value when last trading session closed at $40.13. The company has a market capitalization of $161.9 Billion. The company’s stock has a Return on Assets (ROA) of 7.6 percent, a Return on Equity (ROE) of 18.7 percent and Return on Investment (ROI) of 11.2 percent. The company reached its 52-Week high of $42 on Mar 21, 2016 and 52-Week low of $34.47 on Feb 11, 2016.\n\nEarnings per share (ttm) for Oracle Corporation (NYSE:ORCL) according to Finviz Data is $2.09.\n\nThe growth estimate for Oracle Corporation (NYSE:ORCL) for the current quarter is -3.1 percent. The projected growth estimate for the next quarter is -3.7 percent. The company’s stock has grown by 0.08 percent in the past 5 years. For the next 5 years, the company is expected to grow by 8.46 percent.\n\nThis company was Initiated by Wells Fargo on 11-Jan-17  to Outperform.\n\nThe 32 analysts offering 12-month price forecasts for Oracle have a median target of 45.00, with a high estimate of 52.00 and a low estimate of 31.00. The median estimate represents a +12.14% increase from the last price of 40.13.\n\nFollowing Earnings result, share price were UP 14 times out of last 28 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 33% percent of times. It has met expectations  2  times and missed earnings  6  times.\n\nThe consensus recommendation for Oracle Corporation (NYSE:ORCL) is 1.85. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 1.92. In comparison, the consensus recommendation 60 days ago was at 1.92, and 90 days ago was at 1.96 respectively.\n\nWhen the current quarter ends, Wall Street expects Oracle Corporation to have earnings per share of $0.62.\n\nRevenue is expected to range from 9.16 Billion to 9.39 Billion with an average of 9.25 Billion.\n\nOracle Corporation is one of the world’s leading suppliers of software for information management. The company develops, manufactures, markets and distributes computer software that helps corporations manage and grow their businesses. The company’s software products can be categorized into two broad areas: Systems software and Internet business applications software.\n\nAstraZeneca PLC (NYSE:AZN) belongs to Medical sector closed its last session with a loss of -2.09 percent and closed its previous trading session at $26.72. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $0.97. The company has the Market capitalization of $68.4 Billion. The company’s stock has a Return on Assets (ROA) of 3.9 percent, a Return on Equity (ROE) of 16.5 percent and Return on Investment (ROI) of 11.5 percent. The company reached its 52-Week high of $35.04 on Aug 5, 2016 and 52-Week low of $25.55 on Dec 7, 2016.\n\nThis company was Upgrade by Leerink Partners on 9-Dec-16 to Outperform.\n\nThe 33 analysts offering 12-month price forecasts for AstraZeneca have a median target of 32.00, with a high estimate of 39.21 and a low estimate of 24.31. The median estimate represents a +19.76% increase from the last price of 26.72.\n\nFollowing Earnings result, share price were DOWN 6 times out of last 10 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 66% percent of times. It has met expectations  1 times and missed earnings  3  times.\n\nThe consensus recommendation for AstraZeneca PLC (NYSE:AZN) is 1.5. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 2. In comparison, the consensus recommendation 60 days ago was at 2, and 90 days ago was at 2 respectively.\n\nWhen the current quarter ends, Wall Street expects AstraZeneca PLC to have earnings per share of $0.59.\n\nRevenue is expected to range from 5.43 Billion to 5.58 Billion with an average of 5.5 Billion.\n\nAstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.", "category": "Oracle 1-27-17", "title": "Stocks to Watch For: Oracle Corporation (NYSE:ORCL), AstraZeneca PLC (NYSE:AZN)"}